Developer docs
API playgroundTry for free, no card

Search company profiles

Conor MedSystems

Full company profile

uuid003bfx6

Namestring
Conor MedSystems
Websiteurl
conormed.com
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Conor MedSystems was founded in 1999 and headquartered in Menlo Park, California, with a stated mission to develop innovative controlled vascular drug delivery technology — most plausibly a regulated medical device platform in the drug-delivery or drug-eluting interventional cardiology category based on the firm's description and regulatory exposure. The company was led by Frank Litvack as Chairman and CEO and at one point scaled its workforce into the 501–1,000 employee range, suggesting a meaningful clinical, regulatory, and commercial build-out during its operating period.

Financially, Conor MedSystems raised approximately $38 million across two disclosed venture rounds in 2002 and 2003, with Highland Capital Partners leading the $10 million round in 2002 and Easton Capital leading the $28 million round in 2003. The company subsequently listed on NASDAQ under the ticker CONR but is now delisted, and its primary corporate domain (conormed.com) currently resolves to a parked GoDaddy landing page hosting unrelated third-party men's health content, indicating the entity is no longer operating as an independent, revenue-generating business based on the available evidence. The input data does not disclose pricing models, product SKUs, named customers, geographic footprint, ownership, or acquisition history.

Short descriptiontext

Conor MedSystems was a Menlo Park-based developer of controlled vascular drug delivery technology, founded in 1999 and once listed on NASDAQ as CONR; the company is now delisted and its corporate domain is parked, with no active independent operations evidenced in the input data.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
drug-eluting stents, vascular drug delivery, interventional cardiology devices, coronary stent systems, controlled release implants
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Interventional Cardiology Medical Devices
Social media profiles1 record
Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Conor MedSystems developed controlled vascular drug delivery technology centered on drug-eluting coronary stents for interventional cardiology. Its proprietary platform was designed to deliver therapeutic agents directly to vessel walls via stent-based scaffolds, targeting the treatment of coronary artery disease. The company was a Menlo Park, California-based medical device developer founded in 1999.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Conor MedSystems operates a telemedicine platform for men's health, specifically focused on erectile dysfunction (ED) treatments. The platform offers online consultations with healthcare providers and dispenses ED medications including sildenafil and tadalafil. The source material does not provide details on the company's specific product portfolio or service architecture.

Product and service1 record
1Controlled Vascular Drug Delivery Stent System
CategoryInterventional Cardiology / Drug-Eluting Stents
Description

A drug-eluting coronary stent platform designed to deliver therapeutic agents directly to the vessel wall via a reservoir-based scaffold, intended for use by interventional cardiologists treating coronary artery disease through percutaneous coronary intervention (PCI).

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Conor MedSystems

Interventional Cardiology Medical Devicesconormed.com

Conor MedSystems was a Menlo Park-based developer of controlled vascular drug delivery technology, founded in 1999 and once listed on NASDAQ as CONR; the company is now delisted and its corporate domain is parked, with no active independent operations evidenced in the input data.

What Conor MedSystems does

Conor MedSystems was founded in 1999 and headquartered in Menlo Park, California, with a stated mission to develop innovative controlled vascular drug delivery technology — most plausibly a regulated medical device platform in the drug-delivery or drug-eluting interventional cardiology category based on the firm's description and regulatory exposure. The company was led by Frank Litvack as Chairman and CEO and at one point scaled its workforce into the 501–1,000 employee range, suggesting a meaningful clinical, regulatory, and commercial build-out during its operating period.

Financially, Conor MedSystems raised approximately $38 million across two disclosed venture rounds in 2002 and 2003, with Highland Capital Partners leading the $10 million round in 2002 and Easton Capital leading the $28 million round in 2003. The company subsequently listed on NASDAQ under the ticker CONR but is now delisted, and its primary corporate domain (conormed.com) currently resolves to a parked GoDaddy landing page hosting unrelated third-party men's health content, indicating the entity is no longer operating as an independent, revenue-generating business based on the available evidence. The input data does not disclose pricing models, product SKUs, named customers, geographic footprint, ownership, or acquisition history.

Conor MedSystems firmographics

Firmographics
Name
Conor MedSystems
Website
https://conormed.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
101–250 employees
Short description
Conor MedSystems was a Menlo Park-based developer of controlled vascular drug delivery technology, founded in 1999 and once listed on NASDAQ as CONR; the company is now delisted and its corporate domain is parked, with no active independent operations evidenced in the input data.
Ownership category
akta.pro rank

Where Conor MedSystems is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Markets served

Conor MedSystems business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Conor MedSystems product offering

Product offering

Core offering

Conor MedSystems developed controlled vascular drug delivery technology centered on drug-eluting coronary stents for interventional cardiology. Its proprietary platform was designed to deliver therapeutic agents directly to vessel walls via stent-based scaffolds, targeting the treatment of coronary artery disease. The company was a Menlo Park, California-based medical device developer founded in 1999.

Product overview

Conor MedSystems operates a telemedicine platform for men's health, specifically focused on erectile dysfunction (ED) treatments. The platform offers online consultations with healthcare providers and dispenses ED medications including sildenafil and tadalafil. The source material does not provide details on the company's specific product portfolio or service architecture.

Differentiator

Problem solved

Functional benefit

Products and services

  • Controlled Vascular Drug Delivery Stent System A drug-eluting coronary stent platform designed to deliver therapeutic agents directly to the vessel wall via a reservoir-based scaffold, intended for use by interventional cardiologists treating coronary artery disease through percutaneous coronary intervention (PCI).

Companies that use Conor MedSystems

Customer profile

Ideal customer profiles1 record

Conor MedSystems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Conor MedSystems partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights1 record

Conor MedSystems competitors and assessment

Company assessment

Market position

Weaknesses4 records

Competitive moat2 records

Customer concentration

Conor MedSystems social profiles

Digital presence

Conor MedSystems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Conor MedSystems leadership team

Management profile

Number of profiles

Profiles1 record

Conor MedSystems funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Conor MedSystems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Conor MedSystems

What does Conor MedSystems do?

Conor MedSystems developed controlled vascular drug delivery technology centered on drug-eluting coronary stents for interventional cardiology. Its proprietary platform was designed to deliver therapeutic agents directly to vessel walls via stent-based scaffolds, targeting the treatment of coronary artery disease. The company was a Menlo Park, California-based medical device developer founded in 1999.

When was Conor MedSystems founded?

Conor MedSystems was founded in 1999. It employs 101 to 250 people.

Where is Conor MedSystems based?

Conor MedSystems is headquartered in Menlo Park, United States, in the North America region.

Does Conor MedSystems have an API?

No public API is recorded for Conor MedSystems.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales